Biogen Idec and Isis Pharmaceuticals target spinal muscular atrophy

Friday, January 6, 2012 09:58 AM

Biogen Idec and Isis Pharmaceuticals have entered into an exclusive, global option and partnership agreement under which they will jointly develop and commercialize ISIS-SMNRx, an antisense investigational drug that treats spinal muscular atrophy (SMA) by compensating for the underlying genetic defect that causes the disease.

The agreement awards Isis an upfront payment of $29 million, with the possibility to receive up to $45 million in milestone payments. While Isis will be responsible for global development of ISIS-SMNRx through phase II/III trials, Biogen Idec has the option to license ISIS-SMNRx until a successful phase II/III trial is completed. If Biogen Idec exercises its option, it will assume global development, regulatory, and commercialization responsibilities.

"SMA is a heartbreaking disease -- it can kill children before their second birthday and there are currently no therapies to treat the disease," said George A. Scangos, Ph.D., CEO of Biogen Idec. “Isis's antisense compound has the potential to be a highly effective, first-to-market therapy for this deadly disease.”

Isis initiated the first phase I clinic study evaluating ISIS-SMNRx in children with SMA in December 2011. Isis plans to follow this study with a phase I multiple-dose study.

 

Share:          
CWWeekly

January 19

Roche takes $1B majority stake in Foundation Medicine to use genomic testing to personalize oncology treatments

BRANY launches software, iPad app to streamline protocol creation for investigator-initiated trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs